Abstract:BackgroundSalvage radiotherapy (SRT) for prostate cancer (PCa) recurrence after prostatectomy offers long-term biochemical control in about 50–60% of patients. SRT is commonly initiated in patients with serum PSA levels < 1 ng/mL, a threshold at which standard-of-care imaging is insensitive for detecting recurrence. As such, SRT target volumes are usually drawn in the absence of radiographically visible disease. 68Ga-PSMA-11 (PSMA) PET/CT molecular imaging is highly sensitive and may offer anatomic localization of PCa biochemical recurrence. However, it is unclear if incorporation of PSMA PET/CT imaging into the planning of SRT could improve its likelihood of success. The purpose of this trial is to evaluate the success rate of SRT for recurrence of PCa after prostatectomy with and without planning based on PSMA PET/CT.MethodsWe will randomize 193 patients to proceed with standard SRT (control arm 1, n = 90) or undergo a PSMA PET/CT scan (free of charge for patients) prior to SRT planning (investigational arm 2, n = 103). The primary endpoint is the success rate of SRT measured as biochemical progression-free survival (BPFS) after initiation of SRT. Biochemical progression is defined by PSA ≥ 0.2 ng/mL and rising. The randomization ratio of 1:1.13 is based on the assumption that approximately 13% of subjects randomized to Arm 2 will not be treated with SRT because of PSMA-positive extra-pelvic metastases. These patients will not be included in the primary endpoint analysis but will still be followed. The choice of treating the prostate bed alone vs prostate bed and pelvic lymph nodes, with or without androgen deprivation therapy (ADT), is selected by the treating radiation oncologist. The radiation oncologist may change the radiation plan depending on the findings of the PSMA PET/CT scan. Any other imaging is allowed for SRT planning in both arms if done per routine care. Patients will be followed until either one of the following conditions occur: 5 years after the date of initiation of randomization, biochemical progression, diagnosis of metastatic disease, initiation of any additional salvage therapy, death.DiscussionThis is the first randomized phase 3 prospective trial designed to determine whether PSMA PET/CT molecular imaging can improve outcomes in patients with PCa early BCR following radical prostatectomy.AcronymPSMA-SRT Phase 3 trial.Clinical trial registration■ IND#130649◦ Submission: 04.26.2016◦ Safe-to-proceed letter issued by FDA: 05.25.2016■ UCLA IRB #18–000484,■ First submission: 3.27.2018■ Date of approval: 5.31.2018■ UCLA JCCC Short Title NUC MED 18–000484■ NCI Trial Identifier NCI-2018-01518■ ClinicalTrials.gov Identifier NCT03582774■ First Submitted: 06.19.2018■ First Submitted that Met QC Criteria: 06.27.2018■ First Posted: 07.11.2018■ Last Update Submitted that Met QC Criteria: 07.17.2018■ Last Update Posted: 07.19.2018Trial statusCurrent Trial Status Active as of 08/13/2018Trial Start Date 09/01/2018-ActualPrimary Completion Date 09/01/2023-AnticipatedTrial Completion Date 09/01/2024-Anticipated

68ga-Psma Pet/Ct-Guided Hypofractionated Salvage Radiation Therapy And Simultaneous Integrated Boost For Psma-Avid Sites After Radical Prostatectomy: Safety And High Psa Response

Management of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer

Prognostic value of PSMA PET in predicting long‐term biochemical control following curative intent treatment for prostate cancer

Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]

PSMA PET imaging for evaluation of recurrent or persistent prostate cancer after primary prostate radiation.

Prostate-specific membrane antigen-radioguided surgery salvage lymph node dissection: experience with fifty oligorecurrent prostate cancer patients

Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy

Significance of 99mTc-PSMA SPECT/CT guided salvage lymph node dissection for prostate cancer patients with biochemical recurrence

Efficacy of Adjuvant and Salvage Image-Guided Radiotherapy in Post-Radical Prostatectomy Patients

Baseline PSMA-PET/CT As a Predictor of PSA Persistence Following Radical Prostatectomy in High-Risk Nonmetastatic Prostate Cancer Patients Receiving Neoadjuvant Therapy.

Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes

Clinical Factors Associated With Suspicious 18F-DCFPyL PSMA PET Activity in Patients Initially Managed With Radical Prostatectomy Including Prostate-Specific Antigen < 0.5 ng/mL

Update from the PSMA-dRT trial: A randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer.

A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa

An 18F-MD-PSMA (Multi-Dentate PMSA Imaging Agent) PET/CT in Prostate Cancer Relapse: Results of a Retrospective Trial.

PSMA-based PET as an imaging biomarker of androgen receptor signaling in high-risk localized and locally advanced prostate cancer (PCa).

PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease?

68Ga-PSMA PET/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study

The Association Between [68ga]psma PET/CT Response and Biochemical Progression in Patients with High-Risk Prostate Cancer Receiving Neoadjuvant Therapy

Undetectable PSA predicts outcome after salvage radiotherapy for biochemical recurrence following radical prostatectomy